Glenmark’s Teneligliptin Launch To Shake Up Indian DPP-4 Sector?
This article was originally published in PharmAsia News
Executive Summary
Glenmark has launched teneligliptin, a cut-price generic version of Mitsubishi Tanabe Pharma's dipeptidyl peptidase-4 (DPP-4) inhibitor Tenelia, in India via a dual brand approach and ahead of the original product, in a move that could spark more pricing action in the diabetes sector.
You may also be interested in...
Indian Teneligliptin Saga: Brands Bazaar, Surging Volumes
More than two dozen brands, a sharp spurt in sales volumes and a price decline of over 60% currently appear to characterize the market for the type 2 diabetes therapy teneligliptin in India. And market watchers claim that teneligliptin volumes in the country have surpassed the combined numbers of some of the more established gliptins, including vildagliptin and sitagliptin.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet